Tickers

1. Composite Trajectory Verdict

All three financial statements carry roughly equal weight for QTRX because the company is in a high-cash-burn, acquisition-integration phase where earnings quality, cash runway, and balance-sheet resilience are jointly critical to assessing trajectory.

Composite Trajectory: Deteriorating

Revenue growth is entirely acquisition-driven (Akoya added $21.9M product and $11.8M service revenue in 2025; $18.0M product and $6.7M service in H1 2026) while the legacy Quanterix business contracted (product revenue -11% in 2025, -$6.7M in H1 2026). GAAP gross margin fell from 60.5% (2024) to 46.8% (2025) and further to 41% (H1 2026). Operating losses widened from -$52.6M (2024) to -$125.5M (2025) and -$90.8M in H1 2026 alone. Net cash used in operations nearly doubled from -$35.2M (2024) to -$77.2M (2025) and reached -$23.2M in H1 2026. Cash and marketable securities dropped from $289.1M (Dec 2024) to $118.2M (Dec 2025) to $93.6M (June 2026). Goodwill was fully impaired twice ($6.4M in Q2 2025, $26.9M in Q2 2026) and the IPR&D intangible ($19.3M) was written off in Q1 2026. The company pushed its cash-flow-breakeven target from 2026 to 2027. No offsetting improving trend appears in any statement.

2. Red Flags

• Goodwill impaired twice in 12 months: $6.4M impairment in Q2 2025 (10-K 2025-12-31, MD&A) followed by $26.9M impairment in Q2 2026 (10-Q 2026-06-30, MD&A), eliminating all goodwill from the Akoya acquisition.
• IPR&D intangible fully written off: $19.3M in-process R&D asset impaired in Q1 2026 after termination of the Akoya-assumed Development Agreement (10-Q 2026-06-30, Note 3).
• Gross margin compression despite revenue growth: GAAP gross margin fell from 60.5% (2024) to 46.8% (2025) (10-K 2025-12-31, Statements of Operations) and to 41% in H1 2026 (10-Q 2026-06-30, Statements of Operations).
• Operating cash burn accelerating: Net cash used in operations increased from -$35.2M (2024) to -$77.2M (2025) (10-K 2025-12-31, Cash Flows) and from -$19.5M (H1 2025) to -$23.2M (H1 2026) (10-Q 2026-06-30, Cash Flows).
• Liquidity declining rapidly: Cash, cash equivalents, and marketable securities fell from $289.1M (Dec 2024) to $118.2M (Dec 2025) to $93.6M (June 2026) (10-K 2025-12-31, Balance Sheet; 10-Q 2026-06-30, Balance Sheet).
• Cash-flow-breakeven target delayed: Management moved the target from “2026” (10-K 2025-12-31, Liquidity) to “2027” (10-Q 2026-06-30, Liquidity).
• Legacy business contracting: Legacy Quanterix product revenue decreased $8.7M (-11%) in 2025 (10-K 2025-12-31, MD&A) and $6.7M in H1 2026 (10-Q 2026-06-30, MD&A); legacy service revenue fell $18.8M (-37%) in 2025 and $3.2M in H1 2026.
• Accumulated deficit compounding: Grew from -$470.1M (Dec 2024) to -$577.2M (Dec 2025) to -$643.7M (June 2026) (10-K 2025-12-31, Balance Sheet; 10-Q 2026-06-30, Balance Sheet).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Total revenue was essentially flat year-over-year at $138.9M vs $137.4M in 2025, with the 1% increase entirely attributable to the Akoya acquisition (10-K 2025-12-31, Statements of Operations). GAAP gross profit fell 22% to $65.0M (46.8% margin) from $83.1M (60.5%) in 2024, and declined further to 41% margin in H1 2026 (10-Q 2026-06-30, Statements of Operations). Total operating expenses surged 40% to $190.5M in 2025, driven by $138.0M SG&A (including $16.4M acquisition/integration costs and $10.0M Emission earnout compensation) and a $15.7M impairment/restructuring charge (10-K 2025-12-31, Statements of Operations). In H1 2026, operating expenses reached $119.0M including $46.8M of impairments (goodwill $26.9M + IPR&D $19.3M) (10-Q 2026-06-30, Statements of Operations). Net loss widened from -$38.5M (2024) to -$107.2M (2025) and to -$66.5M in just the first half of 2026 (10-K 2025-12-31, Statements of Operations; 10-Q 2026-06-30, Statements of Operations). Legacy Quanterix product and service revenues declined in every comparable period provided.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Net cash used in operating activities nearly doubled from -$35.2M (2024) to -$77.2M (2025) (10-K 2025-12-31, Cash Flows) and increased from -$19.5M (H1 2025) to -$23.2M (H1 2026) (10-Q 2026-06-30, Cash Flows). The increase in 2025 was driven by a higher net loss adjusted for non-cash items (stock-based compensation $20.7M, depreciation/amortization $15.8M, impairment $7.8M) partially offset by working capital improvements (10-K 2025-12-31, Cash Flows). In H1 2026, the $23.2M burn reflected a -$66.5M net loss adjusted for $46.8M impairment charges and -$14.0M non-cash income from contract termination, plus a $25.3M negative working capital shift (10-Q 2026-06-30, Cash Flows). Investing activities provided $50.2M in 2025 (mainly $215.8M maturities offset by $93.2M acquisitions and $69.8M purchases) and $38.9M in H1 2026 (mainly $47.4M maturities offset by $8.2M purchases) (10-K 2025-12-31, Cash Flows; 10-Q 2026-06-30, Cash Flows). Financing activities were negligible in all periods. End-of-period cash, cash equivalents, and restricted cash fell from $177.0M (Dec 2023) to $59.3M (Dec 2024) to $33.2M (Dec 2025) to $47.5M (June 2026) (10-K 2025-12-31, Cash Flows; 10-Q 2026-06-30, Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Total assets contracted from $418.8M (Dec 2025) to $319.6M (June 2026), a 24% decline in six months (10-K 2025-12-31, Balance Sheet; 10-Q 2026-06-30, Balance Sheet). Goodwill was eliminated, dropping from $26.4M to $0 after the $26.9M Q2 2026 impairment (10-Q 2026-06-30, Note 4). Intangible assets fell from $131.8M to $105.8M due to $6.6M amortization and the $19.3M IPR&D write-off (10-Q 2026-06-30, Note 4). Cash and marketable securities combined declined from $118.2M to $93.6M (10-K 2025-12-31, Balance Sheet; 10-Q 2026-06-30, Balance Sheet). Total liabilities decreased from $123.0M to $82.4M, primarily from reductions in accounts payable ($13.6M→$8.9M), accrued compensation ($15.0M→$10.3M), accrued expenses ($17.6M→$8.5M), deferred revenue ($26.6M→$17.4M), and contingent liabilities ($5.0M→$3.3M) (10-K 2025-12-31, Balance Sheet; 10-Q 2026-06-30, Balance Sheet). Stockholders’ equity eroded from $295.7M to $237.2M as the accumulated deficit deepened from -$577.2M to -$643.7M (10-K 2025-12-31, Balance Sheet; 10-Q 2026-06-30, Balance Sheet).

6. Data Gaps

• Standalone quarterly results for Q3 2025, Q4 2025, and Q1 2026 (only H1 2026 and H1 2025 are directly comparable in the 10-Q 2026-06-30; the 10-Qs for 2025-09-30 and 2026-03-31 were provided but their detailed income statements and cash flows were truncated in the prompt).
• Full-year 2026 results (only H1 2026 available).
• Segment-level profitability or organic vs. acquired revenue breakdowns beyond the legacy/Akoya splits mentioned in MD&A.
• Detailed working capital component trends (inventory days, receivables days, payables days) beyond the net changes shown in cash flow statements.
• Debt maturity schedule beyond operating lease commitments (no term debt appears on the balance sheets provided).